Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/22072741 below:

Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial

Randomized Controlled Trial

Affiliations

• ¹ Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand. a.grey@auckland.ac.nz

• PMID: 22072741
• DOI: 10.1210/jc.2011-2081

Item in Clipboard

Randomized Controlled Trial

Andrew Grey et al. J Clin Endocrinol Metab. 2012 Jan.

• ¹ Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand. a.grey@auckland.ac.nz

• PMID: 22072741
• DOI: 10.1210/jc.2011-2081

Item in Clipboard

Context: Annual iv administration of 5 mg zoledronate decreases fracture risk. The skeletal effects of annual treatment with doses of zoledronate under 4 mg have not been assessed.

Objective: Our objective was to determine the skeletal effects of single doses of zoledronate of 5 mg or less.

Design, setting, and participants: This was a double-blind, randomized, placebo-controlled trial over 1 yr at an academic research center in 180 postmenopausal women with osteopenia.

Intervention: Intervention was a single baseline administration of iv zoledronate in doses of 1, 2.5, or 5 mg, or placebo.

Main outcome measures: The primary endpoint was change in bone mineral density (BMD) at the lumbar spine. Secondary endpoints were change in BMD at the proximal femur and total body and changes in biochemical markers of bone turnover.

Results: After 12 months, change in spine BMD was greater in each of the zoledronate groups than in the placebo group [mean (95% confidence interval) difference vs. placebo was 3.5% (2.2-4.8%) for 1 mg, 4.0% (2.7-5.3%) for 2.5 mg, and 3.6% (2.3-4.9%) for 5 mg zoledronate, P < 0.001 for each dose]. Change in BMD at the total hip was greater in each of the zoledronate groups than the placebo group [mean (95% confidence interval) difference vs. placebo was 2.7% (1.9-3.5%) for 1 mg, 3.6% (2.8-4.4%) for 2.5 mg, and 3.6% (2.8-4.4%) for 5 mg zoledronate, P < 0.001 for each dose]. Each of the bone turnover markers, β-C-terminal telopeptide of type I collagen and procollagen type I N-terminal propeptide, was lower by at least 40% in each of the zoledronate groups than the placebo group throughout the trial (P < 0.001 vs. placebo for each marker for each dose). There was evidence for a dose-dependent effect of zoledronate on each of the markers (P for trend <0.001).

Conclusion: Annual administration of doses of iv zoledronate lower than 5 mg produces substantial antiresorptive effects. Trials assessing the antifracture efficacy of low doses of zoledronate are justified.

PubMed Disclaimer

• Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.

  Grey A, Bolland M, Mihov B, Wong S, Horne A, Gamble G, Reid IR. Grey A, et al. J Bone Miner Res. 2014 Jan;29(1):166-72. doi: 10.1002/jbmr.2009. J Bone Miner Res. 2014. PMID: 23761303 Clinical Trial.

• The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.

  Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. Grey A, et al. J Clin Endocrinol Metab. 2009 Feb;94(2):538-44. doi: 10.1210/jc.2008-2241. Epub 2008 Dec 2. J Clin Endocrinol Metab. 2009. PMID: 19050050 Clinical Trial.

• Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.

  Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Gamble GD, Reid IR. Bolland MJ, et al. J Clin Endocrinol Metab. 2012 Jun;97(6):1922-8. doi: 10.1210/jc.2012-1424. Epub 2012 Mar 14. J Clin Endocrinol Metab. 2012. PMID: 22419728 Clinical Trial.

• Once-monthly dosing: an effective step forward.

  Reid DM. Reid DM. Bone. 2006 Apr;38(4 Suppl 1):S18-22. doi: 10.1016/j.bone.2006.01.153. Epub 2006 Mar 13. Bone. 2006. PMID: 16533625 Review.

• Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis.

  Pinzone MR, Moreno S, Cacopardo B, Nunnari G. Pinzone MR, et al. AIDS Rev. 2014 Oct-Dec;16(4):213-22. AIDS Rev. 2014. PMID: 25300622 Review.

• Effect of 2 mg Versus 4 mg of Intravenous Zoledronic Acid on Bone Mineral Density at the Lumbar Spine in Indian Postmenopausal Women with Osteoporosis: A Double-blind Parallel-arm Randomized Controlled Trial.

  Durgia H, Kamalanathan S, Ramkumar G, Sarkar S, Reddy SVB, Sahoo J, Palui R, Raj H. Durgia H, et al. J Res Pharm Pract. 2021 Aug 3;10(2):71-77. doi: 10.4103/jrpp.JRPP_20_130. eCollection 2021 Apr-Jun. J Res Pharm Pract. 2021. PMID: 34527611 Free PMC article.

• Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis.

  Gazoni FM, Civile VT, Atallah ÁN, Santos FC, Trevisani VFM. Gazoni FM, et al. Sao Paulo Med J. 2023 May 26;141(6):e2022480. doi: 10.1590/1516-3180.2022.0480.R1.27032023. eCollection 2023. Sao Paulo Med J. 2023. PMID: 37255065 Free PMC article.

• Calcium intake and bone mineral density: systematic review and meta-analysis.

  Tai V, Leung W, Grey A, Reid IR, Bolland MJ. Tai V, et al. BMJ. 2015 Sep 29;351:h4183. doi: 10.1136/bmj.h4183. BMJ. 2015. PMID: 26420598 Free PMC article. Review.

• Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.

  Grey A, Bolland MJ, Horne A, Mihov B, Gamble G, Reid IR. Grey A, et al. CMAJ. 2017 Sep 11;189(36):E1130-E1136. doi: 10.1503/cmaj.161207. CMAJ. 2017. PMID: 28893875 Free PMC article. Clinical Trial.

• Gender- and body-site-specific factors associated with bone mineral density in a non-institutionalized Korean population aged ≥50 years.

  Lee KM, Kwon SS, Chung CY, Lee SY, Kim TG, Choi Y, Park MS. Lee KM, et al. J Bone Miner Metab. 2015 Jul;33(4):401-9. doi: 10.1007/s00774-014-0600-z. Epub 2014 Jul 8. J Bone Miner Metab. 2015. PMID: 25001078

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3